---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-034635"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2022-06-23T23:59:59+00:00"
generated_at: "2026-06-24T23:41:32.495899+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics shareholders reject reverse stock split; Nasdaq compliance at risk

## Summary
- Shareholders re-elected directors Robb Knie, David Sarnoff, Graig Springer, Wayne Linsley.
- Ratified Withum as independent auditor for FY2022; approved 2022 Omnibus Equity Incentive Plan.
- Reverse stock split proposal (1:2 to 1:20) failed, with 13,162,362 for, 3,116,563 against.
- Nasdaq minimum bid price compliance deadline is June 28, 2022; company considers special meeting to revisit reverse split.
- Failure to regain compliance could result in delisting from Nasdaq.

## SEC filing metadata
- accession: 0001213900-22-034635
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2022-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390022034635/0001213900-22-034635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390022034635/ea161987-8k_hoththera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-034635
- JSON: https://secwatch.observer/filing/0001213900-22-034635.json
- Plain text: https://secwatch.observer/filing/0001213900-22-034635.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.